Sanofi Pasteur, CureVac Sign Infectious Diseases Vaccine Deal, Win U.S. Government Funding
This article was originally published in The Pink Sheet Daily
Executive Summary
Private German biotech CureVac wins validation for its RNA-vaccine technology platform with Sanofi Pasteur option deal and enters $33 million research collaboration co-funded by U.S defense department.